Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2019
Reporting Period: First Quarter ended March 31, 2019
Context: The filing announces the issuance of a press release detailing financial results for the quarter ended March 31, 2019, and provides a corporate update.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. The text itself does not provide specific values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that a "Corporate Update" was provided alongside the financial results in the referenced press release, but the specific content of this update is not included in the 8-K text.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2019 revenue, net loss, and cash burn figures.
- Verify the "Corporate Update" details regarding clinical trial progress or strategic initiatives mentioned in the press release.
- Confirm the company's cash runway and liquidity status as of March 31, 2019, which are not stated in this summary document.
- Check for any forward-looking statements or guidance updates included in the attached press release.